Literature DB >> 8491233

Study of the efficacy of nicorandil in patients with ischaemic heart disease using Exercise-T1-201 myocardial tomography.

J Yamazaki1, H Ohsawa, T Uchi, M Iida, H Nakano, H Hosoi, T Morishita, Y Yabe, N Koyama, H Komatsu.   

Abstract

The effect of nicorandil on myocardial perfusion in ischaemic heart disease has been studied using exercise-load T1-201 myocardial SPECT (Ex-SPECT). Ex-SPECT was carried out in 12 patients with previous myocardial infarction (OMI) and 9 with angina pectoris (AP) before and after administration of nicorandil 15 mg/day, for three or more weeks; % T1 uptake and the washout rate in infarcted or ischaemic areas were calculated from short axial images using the Bull's eye method. In the OMI group, % T1 uptake and washout rates in the infarction areas improved significantly from 52.4% and 0.25 before nicorandil to 60.4% and 0.38 after it. In the AP group, too, % T1 uptake and washout rates showed a significant improvement from 56.9% and 0.10 before to 69.1% and 0.33 after administration. Six subjects who had not received the drug, and who showed negative washout rates, had high improvement rates when nicorandil was administered, suggesting that the drug could increase myocardial perfusion during exercise loading as well as suppressing coronary spasm. Ex-SPECT was done in 4 subjects before and after nicorandil and after subsequent surgical treatment (PTCA or CABG) and the effects of the two therapies were compared. The washout rate was improved from 0.01 to 0.34 by administration of nicorandil, and a notable increase in coronary artery blood flow was achieved compared to the level after surgical treatment, i.e. 0.50. It was concluded that, normal dosages of nicorandil have a powerful direct effect of dilating the coronary arteries without any influence on preload or afterload.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491233     DOI: 10.1007/BF00271360

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Effect of 2-nicotinamidethyl nitrate (SG 75) on coronary circulation.

Authors:  Y Uchida; N Yoshimoto; S Murao
Journal:  Jpn Heart J       Date:  1978-01

2.  Quantitative relationship between global left ventricular thallium uptake and blood flow: effects of propranolol, ouabain, dipyridamole, and coronary artery occlusion.

Authors:  J A Melin; L C Becker
Journal:  J Nucl Med       Date:  1986-05       Impact factor: 10.057

3.  Effects of nicorandil on coronary circulation in patients with ischemic heart disease: comparison with nitroglycerin.

Authors:  T Aizawa; K Ogasawara; K Kato
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

4.  Effect of nicorandil on exercise performance in patients with effort angina: a multicenter trial using a treadmill exercise test.

Authors:  K Kato; H Asanoi; C Wakabayashi; S Hosoda; A Shiina; K Hosono; A Kurita; K Seki; K Ishida; A Kuroiwa
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

5.  Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris.

Authors:  H Kishida; S Murao
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

6.  Safety of intravenous dipyridamole for stress testing with thallium imaging.

Authors:  S Homma; Y Gilliland; T E Guiney; H W Strauss; C A Boucher
Journal:  Am J Cardiol       Date:  1987-01-01       Impact factor: 2.778

7.  Effects of nicorandil, a new antianginal agent, and nifedipine on collateral blood flow in a chronic coronary occlusion model.

Authors:  K A Lamping; D C Warltier; H F Hardman; G J Gross
Journal:  J Pharmacol Exp Ther       Date:  1984-05       Impact factor: 4.030

8.  Differentiation of transiently ischemic from infarcted myocardium by serial imaging after a single dose of thallium-201.

Authors:  G M Pohost; L M Zir; R H Moore; K A McKusick; T E Guiney; G A Beller
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

9.  Pathogenesis and treatment of angina pectoris at rest as seen from its response to various drugs.

Authors:  H Yasue; S Omote; A Takizawa; M Nagao; K Miwa; H Kato; S Tanaka; F Akiyama
Journal:  Jpn Circ J       Date:  1978-01

10.  Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study.

Authors:  N Hayata; H Araki; M Nakamura
Journal:  Am Heart J       Date:  1986-12       Impact factor: 4.749

View more
  5 in total

1.  Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction.

Authors:  Shu Kasama; Takuji Toyama; Hisao Kumakura; Yoshiaki Takayama; Shuichi Ichikawa; Tadashi Suzuki; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

2.  Assessment of the severity of coronary artery stenosis by the ratio of the regional washout rate determined by adenosine triphosphate stress Tl-201 SPECT.

Authors:  H Teragawa; T Yamagata; M Kato; M Hiraga; H Matsuura; G Kajiyama
Journal:  J Nucl Cardiol       Date:  1999 May-Jun       Impact factor: 5.952

3.  Clinical application of three-dimensional myocardial imaging: evaluation of efficacy of medical treatment on myocardial perfusion.

Authors:  J Yamazaki; H Hosoi; S Ishiguro; H Muto; H Yamashina; T Morishita; M Takano; J Sugita; M Takahashi
Journal:  Ann Nucl Med       Date:  1996-11       Impact factor: 2.668

4.  Double-blind comparison of the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility.

Authors:  A Baumbach; U Braun; G Döring; K K Haase; W Voelker; K R Karsch
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

5.  Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms.

Authors:  H Yamabe; H Namura; T Yano; H Fujita; S Kim; M Iwahashi; K Maeda; M Yokoyama
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.